216 related articles for article (PubMed ID: 31210529)
1. Efficacy and Safety of Tofogliflozin on 24-h Glucose Profile Based on Continuous Glucose Monitoring: Crossover Study of Sodium-Glucose Cotransporter 2 Inhibitor.
Kurozumi A; Okada Y; Shimokawa M; Goshima Y; Otsuka T; Narisawa M; Torimoto K; Tanaka Y
Diabetes Technol Ther; 2019 Jul; 21(7):385-392. PubMed ID: 31210529
[No Abstract] [Full Text] [Related]
2. Comparison of tofogliflozin 20 mg and ipragliflozin 50 mg used together with insulin glargine 300 U/mL using continuous glucose monitoring (CGM): A randomized crossover study.
Takeishi S; Tsuboi H; Takekoshi S
Endocr J; 2017 Oct; 64(10):995-1005. PubMed ID: 28824042
[TBL] [Abstract][Full Text] [Related]
3. Glucose-lowering effects of 7-day treatment with SGLT2 inhibitor confirmed by intermittently scanned continuous glucose monitoring in outpatients with type 1 diabetes. A pilot study.
Kurozumi A; Okada Y; Tanaka Y
Endocr J; 2021 Mar; 68(3):361-369. PubMed ID: 33208570
[TBL] [Abstract][Full Text] [Related]
4. [Short-term Glucose Lowering Effects of Sodium-glucose Cotransporter 2 Inhibitors Confirmed by Flash Glucose Monitoring in Two Outpatients with Type 1 Diabetes].
Habu M; Okada Y; Kurozumi A; Tanaka Y
J UOEH; 2020; 42(4):359-364. PubMed ID: 33268615
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Tofogliflozin and Ipragliflozin for Patients with Type-2 Diabetes: A Randomized Crossover Study by Flash Glucose Monitoring.
Kawaguchi Y; Sawa J; Kumeda Y
Diabetes Ther; 2020 Dec; 11(12):2945-2958. PubMed ID: 33063270
[TBL] [Abstract][Full Text] [Related]
6. Comparison of the Pharmacokinetic and Pharmacodynamic Relationship of Ipragliflozin Between Patients With Type 1 and Type 2 Diabetes Mellitus.
Toyoshima J; Saito M; Kaibara A; Isaka H; Sakatani T
Clin Ther; 2020 Sep; 42(9):1787-1798.e3. PubMed ID: 32839028
[TBL] [Abstract][Full Text] [Related]
7. Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.
Nagata T; Fukazawa M; Honda K; Yata T; Kawai M; Yamane M; Murao N; Yamaguchi K; Kato M; Mitsui T; Suzuki Y; Ikeda S; Kawabe Y
Am J Physiol Endocrinol Metab; 2013 Feb; 304(4):E414-23. PubMed ID: 23249697
[TBL] [Abstract][Full Text] [Related]
8. Switching Dipeptidyl Peptidase-4 Inhibitors to Tofogliflozin, a Selective Inhibitor of Sodium-Glucose Cotransporter 2 Improve Arterial Stiffness Evaluated by Cardio-Ankle Vascular Index in Patients with Type 2 Diabetes: A Pilot Study.
Bekki M; Tahara N; Tahara A; Igata S; Honda A; Sugiyama Y; Nakamura T; Sun J; Kumashiro Y; Matsui T; Fukumoto Y; Yamagishi SI
Curr Vasc Pharmacol; 2019; 17(4):411-420. PubMed ID: 29766812
[TBL] [Abstract][Full Text] [Related]
9. A novel and selective sodium-glucose cotransporter-2 inhibitor, tofogliflozin, improves glycaemic control and lowers body weight in patients with type 2 diabetes mellitus.
Ikeda S; Takano Y; Cynshi O; Tanaka R; Christ AD; Boerlin V; Beyer U; Beck A; Ciorciaro C; Meyer M; Kadowaki T
Diabetes Obes Metab; 2015 Oct; 17(10):984-93. PubMed ID: 26179482
[TBL] [Abstract][Full Text] [Related]
10. Effects of the SGLT2 inhibitor ipragliflozin on food intake, appetite-regulating hormones, and arteriovenous differences in postprandial glucose levels in type 2 diabetic rats.
Tahara A; Kondo Y; Takasu T; Tomiyama H
Biomed Pharmacother; 2018 Sep; 105():1033-1041. PubMed ID: 30021338
[TBL] [Abstract][Full Text] [Related]
11. Tofogliflozin, a potent and highly specific sodium/glucose cotransporter 2 inhibitor, improves glycemic control in diabetic rats and mice.
Suzuki M; Honda K; Fukazawa M; Ozawa K; Hagita H; Kawai T; Takeda M; Yata T; Kawai M; Fukuzawa T; Kobayashi T; Sato T; Kawabe Y; Ikeda S
J Pharmacol Exp Ther; 2012 Jun; 341(3):692-701. PubMed ID: 22410641
[TBL] [Abstract][Full Text] [Related]
12. Effect of Sodium-Glucose Cotransport-2 Inhibitors on Blood Pressure in People With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis of 43 Randomized Control Trials With 22 528 Patients.
Mazidi M; Rezaie P; Gao HK; Kengne AP
J Am Heart Assoc; 2017 May; 6(6):. PubMed ID: 28546454
[TBL] [Abstract][Full Text] [Related]
13. Acute effect of add-on therapy with tofogliflozin, a sodium glucose co-transporter 2 inhibitor, on 24-hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring in patients with type 2 diabetes receiving dipeptidyl peptidase-4 inhibitors.
Iijima T; Hosonuma S; Kurai H; Kajitani H; Sakurai S; Tomaru T; Jojima T; Usui I; Aso Y
Int J Clin Pract; 2021 Nov; 75(11):e14732. PubMed ID: 34388297
[TBL] [Abstract][Full Text] [Related]
14. Sodium-Glucose Cotransporter 2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
Vivian E
Diabetes Educ; 2015 Dec; 41(1 Suppl):5S-18S. PubMed ID: 26450220
[TBL] [Abstract][Full Text] [Related]
15. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
Sands AT; Zambrowicz BP; Rosenstock J; Lapuerta P; Bode BW; Garg SK; Buse JB; Banks P; Heptulla R; Rendell M; Cefalu WT; Strumph P
Diabetes Care; 2015 Jul; 38(7):1181-8. PubMed ID: 26049551
[TBL] [Abstract][Full Text] [Related]
16. Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: preclinical and clinical data.
Kurosaki E; Ogasawara H
Pharmacol Ther; 2013 Jul; 139(1):51-9. PubMed ID: 23563279
[TBL] [Abstract][Full Text] [Related]
17. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
[TBL] [Abstract][Full Text] [Related]
18. SGLT2 inhibitor ipragliflozin alone and combined with pioglitazone prevents progression of nonalcoholic steatohepatitis in a type 2 diabetes rodent model.
Tahara A; Takasu T
Physiol Rep; 2019 Nov; 7(22):e14286. PubMed ID: 31782258
[TBL] [Abstract][Full Text] [Related]
19. Long-term safety and efficacy of the sodium-glucose cotransporter 2 inhibitor, tofogliflozin, added on glucagon-like peptide-1 receptor agonist in Japanese patients with type 2 diabetes mellitus: A 52-week open-label, multicenter, post-marketing clinical study.
Terauchi Y; Fujiwara H; Kurihara Y; Suganami H; Tamura M; Senda M; Gunji R; Kaku K
J Diabetes Investig; 2019 Nov; 10(6):1518-1526. PubMed ID: 31033218
[TBL] [Abstract][Full Text] [Related]
20. Tofogliflozin: first global approval.
Poole RM; Prossler JE
Drugs; 2014 Jun; 74(8):939-44. PubMed ID: 24848755
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
